



## ASX ANNOUNCEMENT

### Market Update: COVID-19

**Sydney, 26 March 2020.** Actinogen Medical ASX: ACW ('ACW' or 'the Company') provides an update on the impact to the Company of the COVID-19 pandemic.

Fortunately, the impact of the COVID-19 pandemic on Actinogen Medical at this stage is limited, with the Company's primary focus on future trial planning and data analysis unhindered, and with all Actinogen staff continuing to work on these important tasks. Future clinical trial planning is progressing on studies in Alzheimer's disease, and cognitive impairment associated with schizophrenia, and diabetes, and we continue to make a range of grant applications to support the funding of these studies. Additionally, active discussions with key strategic parties for these target indications continue and the Company is exploring additional development opportunities as they arise.

Understandably, COVID-19 has caused delays in clinical research and laboratory work globally, with increased demands on healthcare systems and restrictions to staff attending their normal places of work. Actinogen acknowledges that, depending on how long COVID-19 continues to impact the overall healthcare system, commencement of the planned new clinical studies may need to be delayed.

Currently, Actinogen has one active clinical trial, the Phase I Target Occupancy study - being conducted in Melbourne, Australia - and several active pre-clinical toxicology studies. Patient enrolment for the Target Occupancy study has been put on hold until further notice, in-line with the directive given by the TGA and other global regulatory agencies that patient safety and well-being must take precedence. Fortunately, this study is well progressed, with most patients already enrolled and adequate data available to feed into the detailed data analyses currently being undertaken. The pre-clinical studies - being conducted in the UK and France - are likewise impacted given the global directive that employees work from home.

Actinogen remains in a strong capital position, with A\$8.5m held in cash as at 31 December 2019, and no major capital commitments yet made for future studies. Corporate expenses are being minimised and carefully managed.

Actinogen CEO and MD, Dr. Bill Ketelbey, said: "The COVID-19 pandemic is having a global impact and we all know this is a challenging time. At Actinogen, we are taking the necessary health and safety precautions to protect our staff, collaborators, study participants and the broader community.

"We are fortunate the impact on Actinogen operations has been limited. We continue to work remotely and progress the ongoing data analysis and planning of our future trials. We remain in a strong capital position and are actively monitoring the evolving situation. We look forward to coming out of this crisis in a strong position to initiate our promising trial program to further progress the development of Xanamem."

## ENDS

**Actinogen Medical**  
Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401

**Investor and Media Enquiries**  
Arthur Chan  
WE Communications  
P: +61 2 9237 2805

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

E: arthurc@we-worldwide.com

***Announcement authorised by the Board of Directors of Actinogen Medical***

**About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with chronic neurological and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease and cognitive impairment associated with schizophrenia and diabetes. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

**About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other therapies for Alzheimer's disease. It works by blocking the excess production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain, affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease and schizophrenia and in metabolic diseases like diabetes.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, showed that the drug exhibited a good safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition, which, along with other data recently generated, confirms the underlying mechanism of action of Xanamem.

The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2020, including in Alzheimer's disease, and in cognitive impairment associated with schizophrenia and diabetes.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

**Disclaimer**

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB [www.actinogen.com.au](http://www.actinogen.com.au)